The goal of this study is to identify chemical compounds in the blood and sputum (i.e., biomarkers) that are associated with objective measurements of health status in patients with cystic fibrosis (CF). This study builds upon observations that blood levels of hepcidin-25, a protein that regulates how the body uses and stores iron, vary during CF pulmonary exacerbation (CFPE).
Study Type
OBSERVATIONAL
Enrollment
20
Hospitalization for comprehensive treatment of CF pulmonary exacerbation, including intravenous (IV) antibiotics, nutritional assessment and support, airway clearance of mucus, use of inhaled mucolytic agents and bronchodilators, glycemic control with insulin, and psychosocial support.
Maine Medical Center
South Portland, Maine, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Change in Serum Hepcidin-25 Concentration After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment
The primary endpoint of this study is the characterization of 3 groups (i.e., "low," "intermediate," and "high") of serum hepcidin-25 responders to CFPE treatment. Response will be defined as the ratio of post- to pre-treatment serum hepcidin-25 concentration for each subject.
Time frame: Duration of hospitalization, an expected average of 12 days
Change in Percent-Predicted Forced Expiratory Volume in One Second (FEV1%) After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment
Post- to pre-treatment ratio for FEV1% for each subject.
Time frame: Duration of hospitalization, an expected average of 12 days
Change in Body Mass Index (BMI) After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment
Post- to pre-treatment ratio for BMI for each subject.
Time frame: Duration of hospitalization, an expected average of 12 days
Change in CFRSD-CRISS Score After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment
CFRSD-CRISS is a patient-reported outcome (PRO) instrument developed by the Seattle Quality of Life Group at the University of Washington and used herein under license to evaluate the severity of symptoms of CF in adults and adolescents (≥12 years) with a chronic respiratory infection. Symptoms assessed in the CFRSD-CRISS are: difficulty breathing, cough, cough up mucus, chest tightness, wheeze, feeling feverish, tired, and chills/sweats. The 8 items quantify symptom severity for the previous 24 hours to capture the magnitude of symptoms in stable CF, during medically treated CF exacerbations, and during recovery from an exacerbation. We will determine the within-subject differences in CFRSD-CRISS score associated with CFPE treatment.
Time frame: Duration of hospitalization, an expected average of 12 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change in Serum Iron After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment
Post- to pre-treatment ratio for serum iron concentration for each subject.
Time frame: Duration of hospitalization, an expected average of 12 days
Change in Serum Interleukin-6 (IL-6) Concentration After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment
Post- to pre-treatment ratio for serum interleukin-6 (IL-6) concentration for each subject.
Time frame: Duration of hospitalization, an expected average of 12 days
Change in Sputum Iron Content After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment
Post- to pre-treatment ratio for sputum iron content for each subject.
Time frame: Duration of hospitalization, an expected average of 12 days
Change in Serum EPO Concentration After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment
Post- to pre-treatment ratio for serum erythropoietin (EPO) for each subject.
Time frame: Duration of hospitalization, an expected average of 12 days
Change in Transferrin Saturation After Hospitalization for CF Pulmonary Exacerbation Treatment
Post- to pre-treatment ratio for transferrin saturation for each subject.
Time frame: Duration of hospitalization, an expected average of 12 days
Change in Serum TREM-1 Concentration After Hospitalization for CF Pulmonary Exacerbation Treatment
Post- to pre-treatment ratio for serum triggering receptor expressed on myeloid cells-1 (TREM-1) for each subject.
Time frame: Duration of hospitalization, an expected average of 12 days
Change in Serum sIL-6R Concentration After Hospitalization for CF Pulmonary Exacerbation Treatment
Post- to pre-treatment ratio for serum soluble IL-6 receptor (sIL-6R) concentration for each subject.
Time frame: Duration of hospitalization, an expected average of 12 days
Change in Hemoglobin Concentration After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment
Post- to pre-treatment ratio for serum hemoglobin concentration for each subject.
Time frame: Duration of hospitalization, an expected average of 12 days